BAERLOCHER GABRIELA M ET AL: "Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US , vol. 120, no. 21 1 November 2012 (2012-11-01), page 179, XP008180577, ISSN: 0006-4971 Retrieved from the Internet: URL:http://www.bloodjournal.org/ (B8)

CATENACCI ET AL: "Myelodysplasic syndromes: A comprehensive review", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 19, no. 6, 1 November 2005 (2005-11-01), pages 301-319, XP005167052, ISSN: 0268-960X, DOI: 10.1016/J.BLRE.2005.01.004 (B8)

CLAUDIO BRUNOLD ET AL: "3843: Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals", BLOOD, vol. 118, no. 21, 18 November 2011 (2011-11-18), - 13 December 2011 (2011-12-13), page 3843, XP055254840, US ISSN: 0006-4971 (B8)

CN-A- 101 220 044 (B8)

FENAUX ET AL (POSTER 4256) ASH (2017): POSTER, 2017, (B8)

US-A1- 2005 282 893 (B8)

KAKIUCHI YASUTAKA ET AL: "Inhibition of Human Tumor Cell Proliferation by the Telomerase Inhibitor TELIN", CYTOLOGIA (TOKYO), vol. 75, no. 2, June 2010 (2010-06), pages 177-183, XP008180568, ISSN: 0011-4545 (B8)

STEENSMA ET AL (ABSTRACT 463) ASH (2018): ASH ORAL PRESENTATION, 2018, (B8)

STEENSMA ET AL (ABSTRACT S1557) EHA (2018): EUROPEAN HEMATOLOGY ASSOCIATION, 2018, (B8)

TAUCHI TETSUZO ET AL: "Activity of a novel G-quadruplex-interactive telomerase inhibitor, SOT-095, against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US , vol. 102, no. 11 16 November 2003 (2003-11-16), page 652a, XP008180575, ISSN: 0006-4971 Retrieved from the Internet: URL:http://www.bloodjournal.org/ (B8)

GABRIELA M BAERLOCHER ET AL: "Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results", ANNUAL MEETING OF THE AM SOCIETY, vol. 120, no. 21, 16 November 2012 (2012-11-16), pages 1-16, XP055254428, (B8)